Literature DB >> 11367532

Cell-specific regulation of the CD21 gene.

M D Zabel1, J H Weis.   

Abstract

The Complement Receptor Type 2 (Cr2-145,CR2, CD21) is an important receptor in the innate and acquired immune response. CD21 is produced by B cells and follicular dendritic cells, where it binds cleavage products of the C3 complement protein. CD21 facilitates internalization of immune complexes by B cells to enhance antigen presentation. CD21, in association with CD19/CD81, also serves as a coaccessory activation complex with the B-cell antigen receptor, permitting a lower antigen concentration to achieve maximal B-cell activation. CD21 traps immune complexes on the surface of follicular dendritic cells and displays them to activated B cells in germinal centers. Much work has been conducted to determine the transcriptional control mechanisms dictating CD21 expression. Appropriate transcriptional control of the CD21 gene evidently requires the CD21 promoter, as well as intronic sequences with enhancer and suppressor functions. Chromatin structure has been implicated in regulating the coordination of CD21 promoter and intronic control sequences by regulating access to them by putative transcription factors. This review assesses the past and current research into CD21 transcriptional regulation and offers insight into future experimental directions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11367532     DOI: 10.1016/s1567-5769(00)00046-1

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

1.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Authors:  Jian-Hua Ma; Emilia Patrut; Jan Schmidt; Hanns-Peter Knaebel; Markus W Büchler; Angela Märten
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 2.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

4.  CD21(-/low) B cells in human blood are memory cells.

Authors:  K Thorarinsdottir; A Camponeschi; N Cavallini; O Grimsholm; L Jacobsson; I Gjertsson; I-L Mårtensson
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

5.  Analysis of the regulatory role of BAFF in controlling the expression of CD21 and CD23.

Authors:  Irina Debnath; Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2006-11-30       Impact factor: 4.407

6.  Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation.

Authors:  Sherry D Fleming; Michael R Pope; Sara M Hoffman; Tiffany Moses; Urska Bukovnik; John M Tomich; Lynn M Wagner; Keith M Woods
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

7.  Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells.

Authors:  Manrong Jiang; Kejin Zhu; Jose Grenet; Jill M Lahti
Journal:  Biochim Biophys Acta       Date:  2008-03-10

8.  Genetic depletion of complement receptors CD21/35 prevents terminal prion disease in a mouse model of chronic wasting disease.

Authors:  Brady Michel; Adam Ferguson; Theodore Johnson; Heather Bender; Crystal Meyerett-Reid; Bruce Pulford; Adriana von Teichman; Davis Seelig; John H Weis; Glenn C Telling; Adriano Aguzzi; Mark D Zabel
Journal:  J Immunol       Date:  2012-09-21       Impact factor: 5.422

9.  Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.

Authors:  Edgar D Charles; Rashidah M Green; Svetlana Marukian; Andrew H Talal; Gerond V Lake-Bakaar; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

10.  Deletion of putative intronic control sequences does not alter cell or stage specific expression of Cr2.

Authors:  Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-09-09       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.